Dietary Salt in Postural Tachycardia Syndrome
Primary Purpose
Postural Orthostatic Tachycardia Syndrome
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Blood Volume
Total Blood Volume
Exercise Capacity Test - Bicycle
Posture Study
Sponsored by
About this trial
This is an interventional basic science trial for Postural Orthostatic Tachycardia Syndrome focused on measuring POTS, Orthostatic Intolerance, Orthostatic Tachycardia
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction Center
- Increase in heart rate ≥30 beats/min with position change from supine to standing (10 minutes)
- Chronic symptoms consistent with POTS that are worse when upright and get better with recumbence
- Age between 18-50 years old
- Non-smokers
- Premenopausal patients with POTS and healthy volunteers
- Only female participants are eligible.
- Since 80-90% of POTS patients are female, and there can be differences in measures with the menstrual cycle, including a small number of males might introduce a significant amount of noise.
- Able and willing to provide informed consent
Exclusion Criteria:
- Smokers
- Overt cause for postural tachycardia, i.e., acute dehydration
- Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or screening results
- Pregnant (positive pregnancy test) or breastfeeding
- Hypertension defined as supine resting BP>145/95 mmHg off medications or needing antihypertensive medication
- Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule
- Unable to give informed consent
Sites / Locations
- Vanderbilt University Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
High Sodium Level
Low Sodium Dietary Level
Arm Description
POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The high sodium diet will provide 300 milliequivalents (mEq) sodium/day.
POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The low sodium diet will provide 10 mEq sodium/day.
Outcomes
Primary Outcome Measures
Plasma Volume
Plasma volume (PV) was determined by the indicator tracer-dilution technique, using the DAXOR Blood Volume Analyzer (BVA)-100 system (DAXOR Corporation), on Day 7 of the low sodium and high sodium dietary interventions. Outcome data are the absolute values for PV on Day 7 for each diet.
Secondary Outcome Measures
Magnitude of Suppression of Plasma Renin Activity (From Low Sodium to High Sodium Diets)
Whether upright plasma renin activity was modified appropriately by changes in dietary sodium in POTS & healthy controls. Outcome data are the absolute values for upright plasma renin activity on Day 7 of each diet.
Full Information
NCT ID
NCT01547117
First Posted
March 2, 2012
Last Updated
January 28, 2022
Sponsor
Vanderbilt University
Collaborators
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT01547117
Brief Title
Dietary Salt in Postural Tachycardia Syndrome
Official Title
Dietary Salt in Postural Tachycardia Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
March 2012 (undefined)
Primary Completion Date
December 2020 (Actual)
Study Completion Date
December 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University
Collaborators
National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Patients with POTS may not adequately expand their plasma volume in response to a high-sodium (Na+) diet. Mechanisms involved in the regulation of plasma volume, such as the renin-angiotensin-aldosterone system and renal dopamine, may be impaired in POTS and may respond inappropriately to changes in dietary sodium.The purpose of this study is to determine (1) whether a high dietary sodium level appropriately expands plasma volume in POTS; (2) whether plasma renin activity and aldosterone are modified appropriately by changes in dietary sodium in POTS; and (3) whether patients with POTS have improvements in their orthostatic tachycardia and symptoms as a result of a high dietary sodium level.
Detailed Description
Study Day 1
Start 150 milliequivalents (mEq) Na+/day diet (POTS patients as inpatients; healthy control subjects with clinical research center (CRC)- provided outpatient diet)
Start a 24h urine collection (for Na+, K+, Cr, fractionated catecholamines)
Blood work
Blood volume - carbon monoxide rebreathing
Study Day 2
Complete 24h urine
Start STUDY DIET (10 mEq Na+/day or 300 mEq Na+/day in a random order) after 3 meals of 150 mEq Na+/day are complete; water ad lib
Study Day 3 - 5
Continue STUDY DIET; water ad lib
On Day 5, a 24 hr holter combined ECG monitor will be placed on the subjects.
Study Day 6
Continue STUDY DIET; water ad lib
Remove 24h Holter combined ECG monitor and BP monitor from subject
Start a 24h urine collection (for Na+, K+, Cr, fractionated catecholamines)
Complete questionnaires
Nothing by mouth (NPO) after midnight for study next day
Study Day 7 (BIG DAY)
Awaken early (~6am) to void (still collecting 24h urine)
Patient returns to bed, IV catheter inserted
Posture Study (in morning; between 7-8am ideally)
Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes
We will draw 3 tablespoons of blood in each body position to measure hormones that regulate blood pressure and blood volume
Hormones to verify the subject's phase of menstrual cycle
Serum/plasma aliquots for future analysis
Subjects will rate symptoms during supine period and at end of stand using Vanderbilt Orthostatic Symptoms Score (VOSS)
Total Blood Volume (DAXOR)- using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation blood samples drawn through IV catheter before injection and for ~30 minutes post-injection (total - 25 ml)
This will be done after supine assessment, but before standing the subject up
Autonomic Function Test with Cardiac Output and Brief Tilt
The subject will be tilted up to 60-75 degrees head-up tilt for up to 10 minutes to measure the changes in heart rate and blood pressure and symptoms with upright challenge.
Blood volume - carbon monoxide rebreathing
Exercise Capacity Test (in the afternoon) Will estimate maximal oxygen consumption (VO2 max) This test will be conducted on a stationary bicycle. Effort will be gradually increase while expired air is measured during exhaustive physical work.
All procedures are repeated at least a month later with the 2nd level of dietary salt. (Randomized to high or low salt to the first phase, the second phase is the remaining level)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postural Orthostatic Tachycardia Syndrome
Keywords
POTS, Orthostatic Intolerance, Orthostatic Tachycardia
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Randomization tables will be used to determine whether the 10 mEq sodium/day or 300 mEq sodium/day diet will be consumed first. Both diets will be completed on each subject (randomized crossover study), so all of the study procedures (after screening) will be repeated.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
38 (Actual)
8. Arms, Groups, and Interventions
Arm Title
High Sodium Level
Arm Type
Experimental
Arm Description
POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The high sodium diet will provide 300 milliequivalents (mEq) sodium/day.
Arm Title
Low Sodium Dietary Level
Arm Type
Experimental
Arm Description
POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The low sodium diet will provide 10 mEq sodium/day.
Intervention Type
Radiation
Intervention Name(s)
Blood Volume
Other Intervention Name(s)
carbon monoxide (CO)-red blood cell (RBC) Blood Volume
Intervention Description
we will measure the amount of hemoglobin and myoglobin in the body by a procedure called CO rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.
Intervention Type
Radiation
Intervention Name(s)
Total Blood Volume
Other Intervention Name(s)
DAXOR
Intervention Description
Using injection of iodinated I-131 tagged human serum albumin nominally 25 microcuries of radiation, blood samples are drawn before and 30 minutes after injection.
Intervention Type
Procedure
Intervention Name(s)
Exercise Capacity Test - Bicycle
Other Intervention Name(s)
VO2 Max (maximal oxygen consumption)
Intervention Description
subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
Intervention Type
Procedure
Intervention Name(s)
Posture Study
Other Intervention Name(s)
Standing Orthostatic Challenge
Intervention Description
Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
Primary Outcome Measure Information:
Title
Plasma Volume
Description
Plasma volume (PV) was determined by the indicator tracer-dilution technique, using the DAXOR Blood Volume Analyzer (BVA)-100 system (DAXOR Corporation), on Day 7 of the low sodium and high sodium dietary interventions. Outcome data are the absolute values for PV on Day 7 for each diet.
Time Frame
after 7 days of each dietary sodium level
Secondary Outcome Measure Information:
Title
Magnitude of Suppression of Plasma Renin Activity (From Low Sodium to High Sodium Diets)
Description
Whether upright plasma renin activity was modified appropriately by changes in dietary sodium in POTS & healthy controls. Outcome data are the absolute values for upright plasma renin activity on Day 7 of each diet.
Time Frame
Upright blood samples were collected after up to 30 minutes of standing on the 7th day of each dietary sodium intervention
Other Pre-specified Outcome Measures:
Title
Magnitude of Suppression of Serum Aldosterone (From Low Sodium to High Sodium Diets)
Description
Whether upright serum aldosterone was modified appropriately by changes in dietary sodium in POTS patients & healthy controls. Outcome data are the absolute values for upright serum aldosterone on Day 7 of each diet.
Time Frame
Upright blood samples were collected after up to 30 minutes of standing on the 7th day of each dietary sodium intervention
Title
Magnitude of Orthostatic Tachycardia
Description
Whether the magnitude of the heart rate increase that occurs in patients with POTS when moving from a supine to an upright position is attenuated by a High Sodium diet relative to a Low Sodium diet.
Heart rate was assessed after overnight rest and fasting after midnight, following at least 60 minutes of lying quietly. Heart rate was then measured at intervals after subjects had been standing for up to 30 minutes (as tolerated). Orthostatic tachycardia was calculated as the difference between standing and lying heart rates. Data are presented for 5 minutes standing (or maximal stand if <5 minutes) since several patients were unable to stand for 10 minutes.
Data in POTS patients were compared to that of Healthy Controls.
Time Frame
Supine and upright heart rates were measured on Day 7 of High Sodium and Low Sodium diet.
Title
Upright Symptom Score
Description
Whether upright symptoms were improved in patients with POTS on a High Sodium diet relative to a Low Sodium diet.
Patients were asked to report their standing symptom burden at the end of the Stand portion of the posture study, using the Vanderbilt Orthostatic Symptoms Scale (VOSS). They rated the severity of nine symptoms (palpitations, lightheadedness, mental confusion, blurred vision, shortness of breath, tremulousness, chest discomfort, headache, and nausea) on a scale from a minimum of 0 (reflecting an absence of symptoms) to a maximum of 10. The sum of the scores for the 9 symptoms was used to measure orthostatic symptom burden. Higher scores represent worse symptoms.
Time Frame
Upright symptoms were assessed on the 7th day of diet.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Diagnosed with postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction Center
Increase in heart rate ≥30 beats/min with position change from supine to standing (10 minutes)
Chronic symptoms consistent with POTS that are worse when upright and get better with recumbence
Age between 18-50 years old
Non-smokers
Premenopausal patients with POTS and healthy volunteers
Only female participants are eligible.
Since 80-90% of POTS patients are female, and there can be differences in measures with the menstrual cycle, including a small number of males might introduce a significant amount of noise.
Able and willing to provide informed consent
Exclusion Criteria:
Smokers
Overt cause for postural tachycardia, i.e., acute dehydration
Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or screening results
Pregnant (positive pregnancy test) or breastfeeding
Hypertension defined as supine resting BP>145/95 mmHg off medications or needing antihypertensive medication
Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule
Unable to give informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alfredo J Gamboa, MD
Organizational Affiliation
Vanderbilt University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
33926653
Citation
Garland EM, Gamboa A, Nwazue VC, Celedonio JE, Paranjape SY, Black BK, Okamoto LE, Shibao CA, Biaggioni I, Robertson D, Diedrich A, Dupont WD, Raj SR. Effect of High Dietary Sodium Intake in Patients With Postural Tachycardia Syndrome. J Am Coll Cardiol. 2021 May 4;77(17):2174-2184. doi: 10.1016/j.jacc.2021.03.005.
Results Reference
derived
Learn more about this trial
Dietary Salt in Postural Tachycardia Syndrome
We'll reach out to this number within 24 hrs